Obermatt

Danaher

NYQ:DHR · US2358511028
Life Sciences Tools & ServicesLarge

360

80
EV / EBIT57
Price / Owner Earnings44
Owner Earnings Yield85
Dividend Yield95
Price/Sales36
EV / Gross Profit49
Price/Book64
Return on Capital49
Cash Return on Capital73
Return on Equity60
EBIT Margin79
Gross Profitability45
Cash Conversion51
Accruals56
Owner Earnings Margin89
Sales growth40
Profit Growth98
Long-Term EPS Growth32
Owner Earnings Growth59
Reinvestment27
Price momentum27
Debt load54
Refinancing23
Debt Payback47
Liquidity93
Analyst ratings76
Opinion Changes69
Price Target Upside79
Market mood75
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Danaher clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
TypePublic Company
ExchangeNYSE
Founded1969
Employees2,781
ISINUS2358511028
Last UpdateApr 2, 2026
Themes
Health DiagnosticsProcess AutomationArtificial IntelligenceBiomedical EngineeringGeneticsDetectors, Sensors and MemsLife ScienceMedical

Description

Danaher Corporation (Danaher) operates as a global science and technology innovator committed to accelerating the power of science and technology to improve human health. Danaher operates through more than 15 operating companies with leadership posi…

Analysis

Middle-of-the-road

Danaher Corporation sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is expensive. The owner-earnings multiple stands at 25.4×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 9% a year, against analyst forecasts of 9%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is sturdy. The company scores 8/20 on our value-creation score: creating some value.

Flags to be aware of: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
83
2023202420252026

All-time high

98

Feb 2026

All-time low

14

Jan 2024

Average rank

80

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
36
22
17
50
Price/Earnings
39
44
35
45
Price/Book
64
61
50
48
Dividend Yield
95
93
88
84
Value (overall)
87
75
61
87

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Danaher with its peers
Tempus AI
NSQ:TEM
28
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
OmniAb
NMQ:OABI
61
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Nautilus Biotechnology
NAQ:NAUT
26
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Maravai LifeSciences Holdings
NSQ:MRVI
35
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Fortrea
NSQ:FTRE
42
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Sotera Health
NSQ:SHC
59
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →